© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 02, 2009
This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease.
February 14, 2009
Continuous home oxygen therapy for chronic obstructive pulmonary disease seems more cost-effective than other health technologies covered by Medicare, while nocturnal oxygen therapy is not.